BridgeBio Pharma, Inc. (BBIO) Institutional Ownership

Ownership Summary

BridgeBio Pharma, Inc. (NASDAQ:BBIO) showed up in the 13F filings of 451 institutional investors as of March 2026.

• These investors held 106.6% of outstanding shares in March 2026, up from 97.7% in December 2025.
• Their total shares held in BBIO increased 26.06% quarter over quarter, and separately, investors owning BridgeBio Pharma increased 47.87% from a year ago.
• Of these 451 funds, 271 grew their exposure to BridgeBio Pharma, 129 cut back, and 51 maintained positions.
• Altogether, these fund groups held 207.66Mn shares in BBIO by March 2026, up by 42.92Mn shares quarter on quarter, and up 13.22Mn shares year over year.
• As of March 31, 2026, Janus Henderson Group Plc held the largest stake in BridgeBio Pharma with 26.36Mn shares, accounting for 13.53% of total shares outstanding.
• The most significant purchases of BBIO for the quarter ending March 2026 came from Janus Henderson Group Plc (15.36Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (8.08Mn), VANGUARD CAPITAL MANAGEMENT LLC (7.76Mn), PRICE T ROWE ASSOCIATES INC /MD/ (3.8Mn), CITADEL ADVISORS LLC (2.48Mn).
• The largest sellers of BridgeBio Pharma for the quarter ending March 2026 were VIKING GLOBAL INVESTORS LP (2.55Mn), Goldman Sachs Group Inc (1.67Mn), Laurion Capital Management LP (1.54Mn), Capital Research Global Investors (1.17Mn), DRIEHAUS CAPITAL MANAGEMENT LLC (534.3K).
• Per Business Quant, the top 10 investors in BBIO for the quarter ending March 2026 include Janus Henderson Group Plc (26.36Mn), BlackRock, Inc. (14.21Mn), Kohlberg Kravis Roberts & Co. L.P. (13.26Mn), VIKING GLOBAL INVESTORS LP (11.84Mn), FARALLON CAPITAL MANAGEMENT, L.L.C. (9.37Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (8.08Mn), VANGUARD CAPITAL MANAGEMENT LLC (7.76Mn), Aisling Capital Management LP (5.09Mn), State Street Corp (4.93Mn), GEODE CAPITAL MANAGEMENT, LLC (4.92Mn).